logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Lenvatinib is a promising option for targeted therapy in advanced pancreatic and gastrointestinal neuroendocrine tumours

The treatment with tyrosine kinase inhibitor lenvatinib improves the overall response rate in this group of patients with pre-treated and difficult-to-treat advanced neuroendocrine tumours with the potential for good progression-free survival